BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 33324975)

  • 1. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
    Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
    Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma.
    Sun YY; Li S; Liu C; Pan Y; Xiao Y
    Aging (Albany NY); 2024 May; 16(10):8747-8771. PubMed ID: 38771129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of a novel redox-related lncRNA prognostic signature in lung adenocarcinoma.
    Ren J; Wang A; Liu J; Yuan Q
    Bioengineered; 2021 Dec; 12(1):4331-4348. PubMed ID: 34338158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a RNA-Seq Based Prognostic Signature with Seven Immune-Related lncRNAs for Lung Adenocarcinoma.
    You J; Fang W; Zhao Q; Chen L; Chen L; Chen F
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
    Jin D; Song Y; Chen Y; Zhang P
    Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
    Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
    Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of the association between tumor-infiltrating immune cells and the prognosis of lung adenocarcinoma.
    Pan Y; Sha Y; Wang H; Zhuang H; Ren X; Zhu X; Wei X
    J Cancer Res Ther; 2020; 16(2):320-326. PubMed ID: 32474519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
    Liu J; Wu H; Gao Z; Lou M; Yuan K
    Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
    Chen Y; Zhang X; Li J; Zhou M
    J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of six immune-related lncRNA signature prognostic model for smoking-positive lung adenocarcinoma.
    Zhou D; Wang J; Liu X
    J Clin Lab Anal; 2022 Jun; 36(6):e24467. PubMed ID: 35561270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma.
    Yao B; Wang L; Wang H; Bao J; Li Q; Yu F; Zhu W; Zhang L; Li W; Gu Z; Fei K; Zhang P; Zhang F; Huang X
    Aging (Albany NY); 2021 Apr; 13(8):11381-11410. PubMed ID: 33839701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
    Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
    Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.